A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. "Easy access and good communication among surgeons, medical oncologists and reproductive endocrinologists is critical, " said Lynn Westphal, MD, associate professor, department of obstetrics and gynecology, Stanford University School of Medicine, Stanford, CA. Frequently, young women who are diagnosed with breast cancer must make difficult decisions about surgical treatment options as well as chemotherapeutic treatments that may permanently impair their fertility or delay childbearing.
New Mayo Clinic research has found that robotic surgery for vaginal prolapse (http://www.mayoclinic.org/pelvic-organ-prolapse/) dramatically reduces patient hospital stay and recovery time. These findings are being presented this week at the North Central Section of the American Urological Association in Scottsdale, Ariz. Vaginal prolapse is a condition in which structures such as the uterus, rectum, bladder, urethra, small bowel, or the vagina itself may begin to prolapse, or fall, from their normal positions. Without treatment or surgery, these structures may eventually prolapse farther into the vagina or even through the vaginal opening if their supports weaken enough.
SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women. This key study was presented in an oral presentation at the North American Menopause Society (NAMS) 20th annual meeting. A second oral presentation reported peer-reviewed data that documented for the first time the pharmacokinetics, or absorption and distribution in the body, in U.S. menopausal women of S-equol when taken as a supplement using SE5-OH containing Natural S-equol. Development and ongoing research of SE5-OH containing Natural S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co.
Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. The research, published in the Oct. 12 issue of the Archives of Internal Medicine, is based on data from more than 16, 000 participants in the Women's Health Initiative estrogen-plus- progestin clinical trial. This trial was abruptly halted in July 2002 when researchers found that healthy menopausal women on the combination therapy had an elevated risk for invasive breast cancer.
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy For Menopausal Hot Flashes
Depomed, Inc. (NASDAQ:DEPO) announced top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes. In the higher dose treatment arm of the two doses evaluated, the 1800mg dose achieved positive results at 4 weeks. All four co-primary endpoints of the 1800mg dose at 4 weeks demonstrated significant reductions in frequency and severity in both clinical trials (p-values ranged from 0.0001 to 0.004). Of the other four co-primary endpoints of the 1800mg dose at 12 weeks, one endpoint was positive (p=0.
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21. Women in menopause who have symptoms, but have not had a hysterectomy are currently treated with a combination of estrogen plus progestin hormone therapy, but this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin. To find a better way of administering hormone therapy without the breast cancer risk, Hugh S.